Table 3. Pneumococcal vaccination coverages with PPsV23, PCV13, dual vaccination, or any vaccine, by age subgroups and risk strata among adults aged over 50 years, Catalonia, Spain, 2017 (n = 2,057,656).
| Age groups | PPsV23 | PCV13 | PCV13 + PPsV23 | PCV13 or PPsV23 | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| Aged 50–64 years | ||||||||
| Healthy (n = 595,395) | 25,157 | 4.2 | 705 | 0.1 | 300 | 0.1 | 25,562 | 4.3 |
| At-riska (n = 385,743) | 58,318 | 15.1 | 1,097 | 0.3 | 615 | 0.2 | 58,800 | 15.2 |
| High-riskb (n = 58,734) | 11,934 | 20.3 | 2,448 | 4.2 | 1,687 | 2.9 | 12,695 | 21.6 |
| All (n = 1,039,872) | 95,409 | 9.2 | 4,250 | 0.4 | 2,602 | 0.3 | 97,057 | 9.3 |
| Aged ≥ 65 years | ||||||||
| Healthy (n = 459,714) | 275,700 | 60.0 | 1,607 | 0.3 | 1,371 | 0.3 | 275,936 | 60.0 |
| At-riska (n = 414,456) | 315,897 | 76.2 | 3,581 | 0.9 | 3,298 | 0.8 | 316,180 | 76.3 |
| High-riskb (n = 143,614) | 109,873 | 76.5 | 4,169 | 2.9 | 3,793 | 2.6 | 110,249 | 76.8 |
| All (n = 1,017,784) | 701,470 | 68.9 | 9,357 | 0.9 | 8,462 | 0.8 | 702,365 | 69.0 |
| Overall (≥ 50 years) | ||||||||
| Healthy (n = 1,055,109) | 300,857 | 28.5 | 2,312 | 0.2 | 1,671 | 0.2 | 301,498 | 28.6 |
| At-riska (n = 800,199) | 374,215 | 46.8 | 4,678 | 0.6 | 3,913 | 0.5 | 374,980 | 46.9 |
| High-riskb (n = 202,348) | 121,807 | 60.2 | 6,617 | 3.3 | 5,480 | 2.7 | 122,944 | 60.8 |
| All (n = 2,057,656) | 796,879 | 38.7 | 13,607 | 0.7 | 11,064 | 0.5 | 799,422 | 38.9 |
PPsV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
a Individuals considered at risk include immunocompetent persons with any of the following conditions: immunocompromising conditions, chronic pulmonary/respiratory diseases, heart diseases, chronic renal disease, diabetes mellitus, cirrhosis, alcoholism and/or smoking.
b Individuals considered at high risk are immunocompromised persons.